Exscientia Plc (EXAI) has released an update.
Exscientia Plc has committed to an irrevocable undertaking favoring the acquisition of its issued and to-be-issued share capital by Recursion Pharmaceuticals, Inc. The agreement includes strict terms ensuring Exscientia’s shareholders will not entertain other offers and will vote in support of the acquisition. The deal is set to proceed either through a court-sanctioned scheme of arrangement or a takeover offer, as detailed in the transaction agreement.
For further insights into EXAI stock, check out TipRanks’ Stock Analysis page.
